摘要
目的 :探讨川芎嗪联合氨胍对糖尿病肾脏病变的保护作用及其机制。方法 :用链脲佐菌素制作糖尿病大鼠模型 ,分为正常对照组、糖尿病模型组、川芎嗪治疗组、氨胍治疗组和川芎嗪联合氨胍治疗组 ,于第 12周测定各组大鼠肾组织一氧化氮合酶的活性和一氧化氮含量。结果 :川芎嗪合氨基胍治疗组、川芎嗪治疗组、氨胍治疗组大鼠肾组织NOS活性显著高于模型组 (P <0 .0 1) ,NO的含量增加 (P <0 .0 1)。川芎嗪治疗组、氨胍治疗组NOS活性低于正常对照组 (P <0 .0 1) ,NO的含量降低 (P <0 .0 1) ;川芎嗪合氨基胍治疗组与正常组相比无差异。结论 :川芎嗪联合氨基胍能够增强糖尿病大鼠肾组织NOS活性 ,增加NO的含量 。
Objective:To investigate the mechanism of treatment with Tetromethylpragine and Aminoguanidine on diabetic nephropathy.Methods:Diabetic rats were induced by streptozotocin(STZ).They were divided into 5 groups: normal control group, diabetic group including untreated group, Tetromethylpragin-treated group, Aminoguanidine-treated group and Tetromethylpragine and Aminoguanidine-treated group. Renal nitric oxide(NO)amount and the activity of nitric oxide syntheses(NOS)were determinated after 12 weeks.Results:The TMP group and AG group the activities of NOS were reduced markedly compared with the normal control group( P <0.01),but were still above the DM group; and the renal NO amount were increased significantly( P <0.01). The Tetromethylpragine and Aminoguanidine-treated group and the normal control group was alike.Conclusion:The mechanism of treatment with tetromethylpragine and aminoguanidine on diabetic nephropathy may be partly achieved by increasing the activities of NOS in kidney of diabetic rats.
出处
《中国中西医结合肾病杂志》
2003年第5期265-267,共3页
Chinese Journal of Integrated Traditional and Western Nephrology
关键词
川芎嗪
氨胍
糖尿病
大鼠
肾脏
一氧化氮
影响
Diabetic nephropathy Tetromethylpragine Aminoguanidine Nitric oxide synthase